Observational studyMedicine2026
Clinical outcomes of percutaneous cholecystostomy in patients with acute cholecystitis classified according to the Tokyo guidelines, 2018: A single-center, retrospective, observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous cholecystostomy (PC) has emerged as a valuable alternative to early cholecystectomy for managing acute cholecystitis (AC) in high-risk patients, particularly those classified as grade II or III according to the Tokyo Guidelines (TG). However, the criteria for optimal patient selection and predictors of definitive surgical needs remain inadequately defined. This single-center, retrospective study included 30 patients who underwent PC for AC between 2022 and 2025. Patients were classified as having TG18 grade II or III AC. Demographic characteristics, clinical scores (American Society for Anesthesiologists [ASA] and Charlson Comorbidity Index), laboratory parameters (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], and systemic immune-inflammation index [SII]), length of hospital stay, intensive care unit (ICU) and total parenteral nutrition (TPN) needs, and outcomes, including 30-day and 12-month mortality, and the need for interval cholecystectomy, were analyzed. Patients with grade III AC exhibited significantly higher NLR and lower lymphocyte counts (P = .042 and P = .005, respectively). ICU admission, TPN requirements, and 12-month mortality rates were significantly higher in this group. Post-PC cholecystectomy was performed in 30% of patients, and those requiring surgery had higher ASA scores, experienced prolonged hospitalization, and an elevated mortality rate (P < .05). No major PC-related complications were observed. PC was a safe and effective alternative for high-risk patients with AC. However, many patients with higher ASA scores and severe grades still require surgery and experience higher mortality. Accurate patient selection, therefore, is essential to achieve better outcomes and avoid unnecessary procedures. These findings support personalized guideline-based decisions and identify clinical and laboratory factors that may predict the need for surgery and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.